Cabozantinib
- Generic Name
- Cabozantinib
- Brand Names
- Cabometyx, Cometriq
- Drug Type
- Small Molecule
- Chemical Formula
- C28H24FN3O5
- CAS Number
- 849217-68-1
- Unique Ingredient Identifier
- 1C39JW444G
- Background
Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formu...
- Indication
⑴治疗进展的、不能切除的局部晚期或转移的髓性甲状腺癌。
⑵用于舒尼替尼（索坦）治疗失败的晚期肾癌。
- Associated Conditions
- Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, Metastatic Differentiated Thyroid Cancer, Locally advanced Differentiated Thyroid Cancer (DTC), Metastatic Clear Cell Renal Cell Carcinoma (ccRCC), Progressive, metastatic Medullary thyroid cancer
- Associated Therapies
- -
Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Exelixis reports $539.5M in total revenues, $478.1M from Cabozantinib in the U.S., GAAP EPS of $0.40, and non-GAAP EPS of $0.47. The company updates revenue guidance and announces a favorable patent ruling for Cabozantinib. A collaboration with Merck expands the Zanzalintinib development program. A conference call is scheduled for 5:00 PM Eastern Time.
Cabozantinib Shows Significant Progression-Free Survival Benefits in Phase III Trial for Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors
Cabozantinib significantly improved progression-free survival in advanced pancreatic and extra-pancreatic neuroendocrine tumors, potentially becoming the new standard of care, according to the Phase III CABINET trial results.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath